Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is based on the date of sputum conversion. Treatment should be continued until 12 months after sputum conversion. In the vast majority patients have converted after 6 months of treatment, so a 18 months duration in total. Unfortunately, few data are available for MX, as it is rare in USA, but it is the second NTM isolated in France and concerns an increasing number of patients. As it is uncommon in USA, no clinical studies conducted by the pharmaceutical laboratory will be planned. In a murine model of MX infection, the only drug which decreased the number colony formant units in mice lungs, was amikacin. Until now, amikacin was only available intravenously and used only for patients with very severe disease, because of renal and auditory toxicity. Amikacin liposome inhalation suspension (ARIKAYCE®) is amikacin sulfate encapsulated in liposomes for inhalational delivery. ARIKAYCE® increases amikacin uptake into alveolar macrophages, a refuge for NTM organisms; allows biofilm penetration; and limits systemic amikacin exposure ARIKAYCE® has already be tested in a randomized study on M. avium complex (MAC) refractory pulmonary infections. In this study, the culture conversion rate in the ARIKAYCE® group was higher than standard regimen group.

开始日期2024-10-20

申办/合作机构

Centre Hospitalier Universitaire Amiens-Picardie

[+13]

NCT05689450

/ CompletedN/AIIT

Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder: a Prospective, Single-centre Study and PKPD-analysis

The present trial is a single center, prospective, observational pharmacokinetics and pharmacodynamics (PKPD) cohort study investigating whether patients suffering from a hematological disorder and treated with amikacin due to febrile neutropenia (FN) achieve the predefined amikacin target concentration (Cmax ≥60 mg/L).

开始日期2022-12-21

申办/合作机构

Universitätsspital Basel

NCT04677569

/ Completed临床3期

ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + background regimen (azithromycin [AZI] + ethambutol [ETH]) compared to the ELC (empty liposome control) + background regimen on participant-reported respiratory symptoms at Month 13.

开始日期2021-04-01

申办/合作机构

Insmed, Inc.

100 项与硫酸阿米卡星脂质体相关的临床结果

登录后查看更多信息

100 项与硫酸阿米卡星脂质体相关的转化医学

登录后查看更多信息

100 项与硫酸阿米卡星脂质体相关的专利（医药）

登录后查看更多信息

10,520

项与硫酸阿米卡星脂质体相关的文献（医药）

2026-12-01·BRAZILIAN JOURNAL OF MICROBIOLOGY

Isolation and characterization of potential probiotic Enterococcus faecalis strains from healthy lambs’ feces

Article

作者: Wang, Longhao ; Yan, Kang ; He, Shaojun ; Deng, Yafei ; Zhang, Liujun

BACKGROUND:

As global animal husbandry begins to reduce the use of antibiotics, finding safe and effective alternatives to antibiotics has become the key to ensuring the healthy and sustainable development of the industry. Probiotics are regarded as one of the most potential alternative strategies because of their functions of regulating intestinal microecological balance and inhibiting pathogenic bacteria.

OBJECTIVE:

This study was performed to determine the potential probiotic Enterococcus faecalis strains from the feces of healthy lambs.

METHODS:

One hundred and fifty-one rectal swabs were collected. BHI (brain heart infusion) medium was used to isolate target E. faecalis strains, and 16 S rRNA was used to identify the type of bacteria. The potential probiotic strain (L118) with high acid resistance and negative for hemolytic and gelatinase activitys was selected and its characteristics including amino acid decarboxylase activity, virulence and antibiotic resistance, bacterial adhesion to solvents, aggregation capability and cellulase and amylase activitys were determined. In addition, animal feeding experiments were conducted about the candidate bacteria in goats.

RESULTS:

A non-hemolytic and gelatinase-negative strain (L118), with a high survival rate in simulated gastric fluid (pH 3.0) and simulated intestinal fluid, was screened from 151 strains of E. faecalis. At the same time, arginine decarboxylase activity and susceptibility to antibiotics such as penicillin, amikacin, vancomycin were observed. Also, L118 displayed high hydrophobicity, low auto-aggregation ability, and strong co-aggregation capacity with pathogenic bacteria (Salmonella typhimurium, Staphylococcus aureus). It also has cellulase and amylase activities. Meanwhile, E. faecalis L118 increased the red blood cells and hemoglobin content in the blood, serum glutathione peroxidase activity and intestinal lactobacillus (P < 0.05).

CONCLUSION:

An E. faecalis strain with high acid resistance was confirmed to possess safety and probiotic properties and provides an application and development of a new feed probiotic additive.

2026-09-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Emergence of KPC-producing hypervirulent Klebsiella pneumoniae in a case of fatal recrudescent liver abscess

Article

作者: Sung, Heungsup ; Kim, Mi-Na ; Park, Kuenyoul ; Won, Eun Jeong

A 76-year-old man with pancreatic cancer was readmitted in septic shock due to a recrudescent liver abscess, previously treated with cefepime for four weeks. While only Klebsiella pneumoniae (KP) without acquired resistance was initially isolated from liver abscess cultures, both carbapenem-susceptible KP (CSKP) and carbapenem-resistant KP (CRKP) were identified from liver abscess and blood cultures during this admission. Whole-genome sequencing revealed that CRKP had a chromosome of ST420 containing yersiniabactin genes, bla_SHV-75, emrD, fosA, and oqxAB, plus two plasmids: IncX3-type carrying bla_KPC-2 and bla_SHV-11, and IncHI1B-type carrying aerobactin genes, salmochelin genes, and rmpA. CSKP was ST889 with KL54 capsular type, harboring an IncFIB/IncFII-type plasmid carrying bla_CTX-M-15, and multiple additional resistance determinants. The patient died despite 11 days of meropenem, amikacin, and colistin combination therapy. This is the first report of a hypervirulent CRKP of ST420 carrying bla_KPC-2.

2026-08-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Clinical characteristics, susceptibility profiles and treatment outcomes of pulmonary disease caused by Mycobacterium paraense

Article

作者: Lima, Karla Valéria Batista ; Souza, Alex Brito ; Monteiro, Jose Tadeu Colares ; Lopes, Maria Luiza ; Nascimento, Jacira da Silva ; Garcia, Ana Judith Pires ; da Costa, Ana Roberta Fusco ; Barretto, Adriana Rodrigues ; Tortoli, Enrico

BACKGROUND:

Mycobacterium paraense is an emerging slow-growing mycobacterium (SGM) within the M. simiae complex. While reported globally in environmental sources, its clinical significance remains poorly understood, except in Pará State, Brazil, where it frequently causes non-tuberculous mycobacterial pulmonary disease (NTM-PD).

METHODS:

We retrospectively studied 13 patients meeting ATS/ERS/ESCMID/IDSA criteria for M. paraense NTM-PD (2000-2018). Identification was confirmed by sequencing 16S rRNA, hsp65, and rpoB genes. Antimicrobial susceptibility testing (AST) used broth microdilution. Treatment outcomes followed the 2018 NTM-NET consensus.

RESULTS:

M. paraense accounted for 8.9% of NTM-PD cases at our center. Median age was 59 years; 92.3% had underlying bronchiectasis. History of tuberculosis (TB) treatment was common (76.9%), with a median diagnostic lag of 26.5 months. Cavitary lesions were significantly associated with smear positivity (p = 0.045). AST showed broad resistance to rifampicin, ethambutol, streptomycin, and ciprofloxacin, but high susceptibility to clarithromycin and amikacin. Patients received empirical macrolide-based regimens (median duration: 18 months); 81.8% of those completing therapy achieved cure (including microbiological cure). No recurrence was observed during follow-up (up to 46 months).

CONCLUSION:

M. paraense is a clinically relevant pathogen in the Amazon, frequently misdiagnosed as TB due to cavitary presentation. The high success rate of macrolide-based regimens suggests that strategies for M. avium complex are effective. Enhanced molecular diagnostics are essential to uncover the true global prevalence of this species.

100

项与硫酸阿米卡星脂质体相关的新闻（医药）

2026-06-03

·疫鉴

肺结核很难治，但一字之差的非结核分枝杆菌，才是更严峻的临床负担

昨天我们聊了幽门螺杆菌的耐药问题，很多读者留言说没想到一个常见的细菌已经给临床带来这么大的挑战。今天我想再聊另一种同样被严重低估的细菌。它的隐蔽性更强，治疗难度更大，甚至很多临床医生都对它缺乏足够的认识。最近我们在推进一项抗感染药物的药效学评价工作，和多位疾控中心的分枝杆菌防控专家深度沟通时，才真正意识到这个疾病的实际负担和被低估的程度。一位从事分枝杆菌研究十几年的专家告诉我：现在全国上报的"肺结核"患者里，每10个就有1个其实不是结核。他们得的是非结核分枝杆菌病，简称NTM。绝大多数人这辈子都没听过这个名字。但它的发病率正在持续上升，在美国、日本等发达国家已经超过了肺结核。而比发病率更值得关注的是，临床可用的有效药物非常有限。很多人以为，随着卡介苗的普及和抗结核药物的应用，分枝杆菌引起的肺病已经被我们控制住了。但事实恰恰相反。一种新的分枝杆菌正在悄悄崛起，它就是非结核分枝杆菌。根据《中国非结核分枝杆菌病诊疗指南（2025年版）》数据：肺结核患者中NTM的检出率，已经从2015年的5.8%升至2023年的11.3%，8年几乎翻了一倍。在浙江、广东等东部发达地区，NTM的年发病率已经突破1.5/10万。这还只是确诊数据。由于症状和肺结核几乎完全一样——咳嗽、咳痰、低热、咯血，影像学表现也高度相似，绝大多数NTM肺病患者最初都被误诊为肺结核，部分研究显示这一比例高达94.7%。很多人吃了半年甚至一年的抗结核药，病情不仅没有好转，反而越来越重，最后才被确诊为NTM。更重要的是，NTM不是人传人的传染病。它广泛存在于我们周围的环境中——自来水、土壤、空气里都有它的身影。免疫力正常的人接触后一般不会发病，但对于老年人、慢阻肺患者、糖尿病患者、长期使用激素或免疫抑制剂的人来说，它是需要警惕的机会性致病菌。比肺结核更复杂的疾病负担很多人以为，既然不是结核，那肯定比结核好治。这是最大的认知误区。 NTM的治疗周期、治疗难度和整体预后，都与肺结核有明显差异。首先是治疗周期更长。肺结核的标准疗程是6个月。而最常见的鸟分枝杆菌复合群（MAC）感染，需要治疗12-18个月。治疗难度最大的脓肿分枝杆菌复合群（MABC）感染，治疗周期更是长达18-24个月。也就是说，一个患者一旦确诊，至少要吃一年以上的药。其次是整体治疗效果仍不理想。肺结核的治愈率已经达到90%以上。而MAC的治疗成功率约为60%，MABC的治疗成功率通常低于40%。很多患者会出现反复复发，需要长期用药控制。未经规范治疗的MABC肺病患者，5年死亡率超过50%。最后是经济负担较重。由于没有专门的药物，所有治疗方案都是多种抗生素的联合使用，而且很多药物不在医保报销范围内。平均每位患者每年的治疗费用在1-2万元，重症耐药患者可达10万元以上。中国每年因NTM病导致的直接医疗支出已经超过50亿元，并且还在以每年15%的速度增长。耐药：临床治疗的核心挑战和幽门螺杆菌一样，耐药是NTM治疗最大的拦路虎。但它的耐药机制，比幽门螺杆菌和肺结核都要复杂得多。首先，绝大多数NTM对一线抗结核药物天然耐药。异烟肼、利福平、吡嗪酰胺这些治疗肺结核的特效药，对70%以上的NTM完全无效。尤其是快速生长型的脓肿分枝杆菌，几乎对所有传统抗生素都有天然抵抗力。其次，单药治疗极易诱导获得性耐药。 NTM的基因组突变率极高，只要有一个细菌产生了耐药突变，整个菌群就会很快获得耐药性。而且这些耐药突变还能在不同菌种之间水平转移，让耐药问题更加复杂。更重要的是生物膜耐药。 NTM能在肺部形成一层致密的生物膜，把自己包裹起来。生物膜能显著降低抗生素的穿透效率，使膜内细菌的药物暴露量不足游离细菌的1%。抗生素只能杀死表面活跃的细菌，对膜内的休眠菌却无能为力。一旦停药，这些休眠菌就会重新繁殖，导致病情复发。而最现实的问题是：我们现在用来治疗NTM的所有药物，没有一个是专门为它研发的。全部都是抗结核药、抗生素的"超说明书使用"。全球近40年，只有一款专门用于NTM的药物获批——阿米卡星脂质体吸入剂（Arikayce），2018年获FDA批准，而且只能用于难治性MAC肺病的二线治疗，无法口服，价格也比较昂贵。很多医生面对NTM患者，只能根据药敏试验结果，一种一种药试，寻找有效的联合方案。中国企业，正在填补全球空白和幽门螺杆菌领域一样，当多数国际药企在2015年后逐渐缩减或终止了NTM新药研发项目时，中国企业成了全球研发的主力军。他们认为NTM是"小众病"，市场规模太小，不值得投入。但他们忽略了一个事实：中国有全球最多的NTM患者，有最迫切的临床需求。好消息是，我们已经看到了曙光。盟科药业的MRX-5，是目前全球进展最快的专门针对NTM的口服新药。它属于新型苯并硼唑类抗生素，针对分枝杆菌的独特靶点设计，与现有药物无交叉耐药。临床前数据显示，MRX-5对最常见的MAC和治疗难度最大的MABC都有良好的抗菌活性，包括多重耐药菌株。 2025年12月，MRX-5完成了澳大利亚I期临床，安全性良好。 2026年1月，它获得了美国FDA的IND批准，即将开展国际多中心IIa期临床。中国I期临床也已完成，正在进行数据分析。除此之外，丹诺医药也在布局NTM管线，其TNBi-2项目目前处于临床前阶段。还有很多科研团队在探索噬菌体疗法、免疫治疗等新型治疗手段。 NTM的问题，本质上是一个"被遗忘"的问题。它提醒我们，公共卫生的版图里，不应该只有那些引起大流行的疾病。每一个患者的需求，都值得被看见。

2026-06-03

·今日头条

2026呼吸病国际大会：肺高压、肺纤维化、慢阻肺和哮喘治疗新希望

标题：好消息！2026年呼吸病国际大会传来新进展——肺高压、肺纤维化、慢阻肺和哮喘治疗有了新希望今年5月，全球呼吸与危重症医学领域最重要的学术会议——美国胸学会（ATS）年会在奥兰多召开，公布了一批处于III期阶段的呼吸疾病新药数据。我们帮您把专业术语"翻译"成大白话，看看哪些病和您或家人有关。肺动脉高压（PAH）：口服新药有望让病情恶化风险大降目前肺动脉高压的标准治疗常需吃多种药，部分前列环素类药物还得皮下注射或静脉泵入，不太方便。新公布的 Ralinepag（一种口服IP受体激动剂），在标准治疗基础上加用后，使患者临床恶化（如住院或病情明显加重）的风险降低了约55% 。这意味着将来符合条件的患者有望通过每天口服一次药，更好地稳住病情、减少恶化。 ⚠️ 该药尚未在全球多地正式获批用于PAH，仍在等待药监部门审评，具体能否用、怎么用请遵从主治医生判断。特发性肺纤维化（IPF）：吸入新药帮助"保住"更多肺功能 IPF患者最怕肺功能（FVC，用力肺活量）逐年下降。传统抗纤维化药（如吡非尼酮、尼达尼布）能延缓进展，但仍有部分患者下降较快。研究中，吸入型曲前列尼尔（Tyvaso/吸入treprostinil）联合常规抗纤维化治疗，一年下来比安慰剂多"保住"了约 111毫升的肺活量（两项的汇总结果），且临床恶化风险也有降低趋势。这为IPF患者提供了潜在的新联合治疗思路。 ⚠️ 吸入曲前列尼尔用于IPF目前在美国等国家仍属研究性用途/超说明书，国内尚未批准此适应症，需等正式获批后方可常规处方。 MAC肺病（鸟分枝杆菌复合群肺病）：新诊断患者也可用吸入抗菌药以往吸入阿米卡星脂质体（ALIS）多用于难治、复发的MAC肺病。新数据显示，刚确诊的MAC肺病患者，在标准多药治疗基础上加用吸入ALIS ，呼吸症状评分改善更明显，细菌转阴率也更高。提示这类吸入抗感染治疗未来可能前移至初治人群。打呼噜/阻塞性睡眠呼吸暂停（OSA）：首款口服药露头长期靠戴呼吸机（CPAP）但戴不住的患者有盼头。 AD109（一种含兴奋成分的复方口服药）在III期研究中使呼吸暂停低通气指数（AHI）明显下降，约23%患者达到疾病缓解，部分人严重程度降级。若最终获批，将是首个非设备类的OSA口服治疗方案——但仍需更多长期安全及心血管获益证据。慢阻肺（COPD）：生物制剂只适合"挑人用" 研究发现，血嗜酸粒细胞升高的慢阻肺患者，使用美泊利珠单抗（Mepolizumab，IL-5单抗）可减少因急性加重导致的急诊或住院约23%。但另一条路——IL-33/ST2抑制剂（Itepekimab、Astegolimab）在大型III期试验中结果不稳定，未普遍达到显著终点。结论：慢阻肺生物制剂不是人人能用，验血挑出嗜酸粒细胞升高的人群才更可能受益。 ️ 重症哮喘：目标从"少犯病"升级为"减激素+少打针" 替泽帕单抗（Tezepelumab）：帮助长期依赖口服激素的重症哮喘患者，在不失控的前提下减少激素用量，降低激素副作用风险。长效IL-5抑制剂（Depemokimab）：尝试半年打一针（而非每2～4周一针），虽未完全证明非劣效，但提示未来给药间隔延长的方向。国产双抗（信达IBI3002，IL-4Rα/TSLP双靶点）：早期数据显示可改善肺功能及炎症指标，尚处早期阶段，值得继续关注。给患者朋友的话以上均为最新临床研究数据，多数药物仍在等待监管机构正式批准或指南更新，距门诊常规开方还需要时间。如果您或家人患有上述疾病： ✅ 坚持规范用药、定期随访复查肺功能/心脏超声 ✅ 有疑问可咨询主治医生是否适合参加正规临床试验 ❌ 切勿自行购药或擅自更改当前治疗方案我们会持续跟踪这些新药在国内外的审批动态，第一时间告诉您！本文仅供健康科普，不能替代执业医师的面对面诊疗建议。往期科普：

2026-06-03

·北京医学感染与传染研究

感染性疾病与治疗 15卷 1-6期

Infectious Diseases and Therapy Volume 15, Issue 1 感染性疾病与治疗 15卷 1期 https://link.springer.com/journal/40121/volumes-and-issues/15-1 Review（综述） 1 How to Better Screen for Blood-Borne Viruses, Specifically HIV, in Hospital Emergency Departments: French and European Perspectives 医院急诊科如何更好地筛查血源性病毒（尤其是HIV）：法国和欧洲视角 Anthony Romain ChauvinBruno George SpireOlivier Bouchaud Pages: 1 - 18 2 Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review 了解新冠疫情后百日咳爆发的流行病学及影响因素：叙述性综述 Juan C. Vargas-ZambranoSorin AbrudanDenis Macina Pages: 19 - 41 Part of 1 collection: Digital Features - Infectious Diseases 所属专题集：数字专题 - 传染病 3 The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review 康替唑胺抗结核的结构、特性及临床应用价值：叙述性综述 Tao ChenWeili LiFan Wu Pages: 43 - 56 4 A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome 综述：多西环素暴露后预防用药及其对抗菌药物耐药性和人体微生物组的影响 Ruben Fernandez-IbanezSantiago MorenoMoises Fernandez Pages: 57 - 84 Original Research（论著） 5 Clinical Impact of Implementing a Specific Clinical Pathway for the Management of Clostridioides difficile Infection 实施特定临床方法治疗艰难梭菌感染的临床影响 Miguel Rodríguez-FernándezRocio HerreroNicolás Merchante Pages: 85 - 100 6 Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status 按年龄和合并症状况划分的呼吸道合胞病毒相关住院成人患者的重症监护病房住院时间和机械通气情况 Caihua LiangYun ZhouElizabeth Begier Pages: 101 - 115 7 Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care 医疗保险覆盖的HIV感染者治疗坚持情况、用药转换情况及护理缺口 Suying LiUche MordiPhyllis C. Tien Pages: 117 - 132 8 High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision 大剂量米诺环素可改善鲍曼不动杆菌群肺炎的预后：一项基于倾向加权队列的研究，并基于最低抑菌浓度提出折点修订见解 Yu-Tao TsengYang-Chuan ChenYung-Chih Wang Pages: 133 - 148 9 Post-cranial Neurosurgery Cutibacterium acnes Infections: Clinical Correlates, Presentation, and Outcomes—A Matched Case–Case–Control Study 颅脑神经外科术后皮肤杆菌属感染：临床相关性、表现及预后——一项匹配病例-病例-对照研究 Neta ShirinOfek ArvivIli Margalit Pages: 149 - 164 10 Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial 从基于富马酸替诺福韦二吡呋酯的方案立即转换与延迟转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者骨密度变化：一项多中心、开放标签、随机临床试验 Yueming ShaoXinping YangJun Chen Pages: 165 - 181 11 Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam–Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales 支持欧洲抗微生物药物敏感性试验委员会（EUCAST）针对肠杆菌科细菌的氨曲南-阿维巴坦最低抑菌浓度敏感性折点的微生物学、临床及药代动力学/药效学数据 Susan R. RaberRujia XieJoseph W. Chow Pages: 183 - 195 12 Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002–2022 利用美国常规医疗记录（2002-2022年）分析成人侵袭性大肠杆菌病的流行病学特征 Mark A. SchmidtMaxim BlumJeroen Geurtsen Pages: 197 - 216 13 Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies 转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者生活质量及治疗满意度：观察性队列研究的汇总分析 Andrea AntinoriYoshiyuki YokomakuMarta Boffito Pages: 217 - 244 14 Dual Transmission Dynamics of Carbapenem Resistance in Pediatric Oncology: Plasmid-Mediated and Clonal Spread of blaNDM-5 Enterobacterales 儿科肿瘤中碳青霉烯类耐药性的双重传播动态：blaNDM-5肠杆菌科的质粒介导与克隆传播 Deena JalalMaryam LotfiLobna Shalaby Pages: 245 - 263 Part of 1 collection:Digital Features - Infectious Diseases 所属专题集：数字专题 - 传染病 15 Cost-Effectiveness Analysis of Aztreonam–Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain 氨曲南-阿维巴坦与黏菌素联合美罗培南治疗西班牙产金属β-内酰胺酶肠杆菌科感染的成本效果分析 Gerardo AguilarPatricia Ruiz-GarbajosaJulián Torre-Cisneros Pages: 265 - 284 16 Synchronous anal HPV Infection in Patients with HPV-Related Gynaecological Diseases: A Prospective Study 人乳头瘤病毒（HPV）相关妇科疾病患者同步肛部HPV感染：一项前瞻性研究 Michał BrzezińskiMaciej Stukan Pages: 285 - 295 17 Growth in Anaerobic Bottles is an Independent Predictor of Mortality in Pseudomonas aeruginosa Bloodstream Infections 厌氧瓶中生长是铜绿假单胞菌血流感染死亡的独立预测因素 Daniel N. MarcoLaura MorataAlex Soriano Pages: 297 - 311 18 Acute and Long-Term Healthcare Utilization and Expenditures for Serious Bacterial Infections among Newborns in US Hospitals 美国医院新生儿严重细菌感染的急性和长期医疗资源利用及费用 Kristen N. NobleKatharina SchleyDerek Weycker Pages: 313 - 325 19 Impact of Risk Stacking on COVID-19–Related Healthcare Utilization: A Real-World Retrospective Cohort Study 风险叠加对新冠相关医疗资源利用的影响：一项现实回顾性队列研究 Frank R. ErnstLeah McGrathAlejandro Cané Pages: 327 - 343 20 Chest Computed Tomography Patterns Associated with Severity in Adults with Respiratory Syncytial Virus Infection: A Retrospective Cohort Study 成人呼吸道合胞病毒感染严重程度相关的胸部计算机断层扫描模式：一项回顾性队列研究 Marie Le GoffYoussef ZaarourNicolas de Prost Pages: 345 - 363 Case Series（病例系列） 21 Management and Resolution of Hypersensitivity Pneumonitis-Related Events in Japanese Patients Treated with Amikacin Liposome Inhalation Suspension in the CONVERT and INS-312 Clinical Trials 在CONVERT和INS-312临床试验中，接受硫酸阿米卡星脂质体吸入混悬液治疗的日本患者发生过敏性肺炎相关事件的管理与解决 Yoshitaka YamazakiTaku NakagawaNaoki Hasegawa Pages: 365 - 379 Letter（读者来信） 22 A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复 Pavo MarijicJulian WitteChristiane Hermann Pages: 381 - 383 23 Letter to the Editor Regarding“The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 致编辑的信：关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析” Kuan-Fu LiaoShih-Wei Lai Pages: 385 - 386 Correction（更正） 24 Correction: Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States 更正：美国复发性艰难梭菌感染粪便微生物群孢子活菌brpk（原SER-109）的预算影响分析 Michele WilsonYoav GolanAlpesh N. Amin Pages: 387 - 387 25 Correction: A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 更正：对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复 Pavo MarijicJulian WitteChristiane Hermann Pages: 389 – 389 Infectious Diseases and Therapy Volume 15, Issue 2 感染性疾病与治疗 15卷 2期 https://link.springer.com/journal/40121/volumes-and-issues/15-2 Review（综述） 1 HepatitisA to E in People with HIV: A Virus-Specific Review of Prevention and Treatment HIV感染者中的甲型至戊型肝炎：针对不同病毒的预防和治疗综述 Kuan-Yin LinYi-Chia HuangChien-Ching Hung Pages: 391 - 415 2 The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies 头孢唑林接种物效应：甲氧西林敏感金黄色葡萄球菌治疗策略中一个未被充分重视的因素 Prakhar SrivastavaElizabeth SingletonRazieh Kebriaei Pages: 417 - 441 3 Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management 老年人群中的脑膜炎球菌病：诊断与治疗的挑战 Muhamed-Kheir TahaCatherine Weil-OlivierSaber Yezli Pages: 443 - 459 4 The Future of Antibiotics and Artificial Intelligence: Some Thoughts from Discovery to Bedside 抗生素与人工智能的未来：从发现到临床应用的一些思考 Daniele Roberto GiacobbeAlessandra Agnese GrossiCesar de la Fuente-Nunez Pages: 461 - 475 Original Research（论著） 5 Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway 挪威成年人中PCV21与PCV20或PPSV23血清型所致肺炎球菌疾病的健康和经济负担估算 Zinan YiAthar Ali TajikKwame Owusu-Edusei Pages: 477 - 490 6 Seven versus Fourteen Days of Antibiotics for Gram-Negative Bacteremia from a Urinary Tract Source: a Systematic Review and Meta-analysis 尿路感染来源的革兰阴性菌血症抗生素治疗7天与14天的系统综述和荟萃分析 Graciela LunaAndrea RodriguezMichael Sabina Pages: 491 - 505 7 Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Healthcare-Associated Bloodstream Infections in Brazil: Results from A Prospective Countrywide Multicenter Study 巴西医疗保健相关血流感染中耐甲氧西林金黄色葡萄球菌的分子流行病学：一项前瞻性全国多中心研究的结果 Laura C. AntochevisLetícia O. SudbrackAlexandre P. Zavascki Pages: 507 - 525 8 Long-Term Antibody Persistence After Hepatitis A Vaccination in Healthy Toddlers: Insights from Modeling 健康幼儿接种甲型肝炎疫苗后长期抗体持久性：基于模型的见解 Carlos EspulHéctor Horacio CuelloLaurent Coudeville Pages: 527 - 538 9 Prevalence of Respiratory Syncytial Virus in Adult Patients with Respiratory Illnesses in Low to Middle-Income Countries: A Systematic Review and Meta-Analyses 中低收入国家成人呼吸道疾病患者中呼吸道合胞病毒的流行率：一项系统综述和荟萃分析 Digant GuptaAmandeep KaurAdriana Guzman-Holst Pages: 539 - 559 10 Novel Diagnostic Marker Interleukin-33 for Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure: A Proof-of-Concept Prospective Study 慢加急性肝衰竭合并侵袭性肺曲霉病的新型诊断标志物白细胞介素-33：一项概念验证前瞻性研究 Lanyue HuangMeng ZhangQin Ning Pages: 561 - 576 11 Testing the Feasibility of a Self-Help Intervention That Includes Lymphatic Drainage to Reduce Fatigue-Related Symptoms Among Patients with Long COVID in General Practice: Experiences from Our Randomized Controlled Trial (RCT) 在全科医疗中测试包含淋巴引流以减轻长期新冠患者疲劳相关症状的自助干预措施的可行性：我们的随机对照试验（RCT）经验 Lisa RisteRaymond PerrinAdrian Heald Pages: 577 - 589 12 Comparative Diagnostic Performance of the 36-Minute STANDARD M10 Fast Assay for Molecular Diagnosis of SARS-CoV-2, InfluenzaA and B, and Respiratory Syncytial Virus in Near-Patient Settings 36分钟STANDARD M10快速检测法在床旁检测中对SARS-CoV-2、甲型和乙型流感病毒以及呼吸道合胞病毒的分子诊断性能比较 Alexander DomnichGiada GarzilloGiancarlo Icardi Pages: 591 - 604 13 Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study 感染奥密克戎的危重症COVID-19患者的临床表型：一项全国性前瞻性队列研究 Etienne AudureauPierre Baythe SEVARVIR investigators Pages: 605 - 628 Brief Report（简报） 14 How do Recent Population-Level RSVpreF Vaccine-Impact Results from the United Kingdom Relate to Previously Reported Vaccine Effectiveness Results? 英国最近公布的RSVpreF疫苗在人群层面的影响结果与之前报告的疫苗有效性结果有何关联？ Negar AliabadiQing LiuElizabeth Begier Pages: 629 - 637 Case Report（病例报告） 15 Continuous Infusion of Aztreonam–Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae 针对OXA-48和NDM-1共产生的ST147型肺炎克雷伯菌感染，采用高负荷剂量后持续输注氨曲南-阿维巴坦 Paul Laffont-LozesFanny VillaRomaric Larcher Pages: 639 - 649 Infectious Diseases and Therapy Volume 15, Issue 3 感染性疾病与治疗 15卷3期 https://link.springer.com/journal/40121/volumes-and-issues/15-3 Commentary（述评） 1 Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease 预防婴儿呼吸道合胞病毒疾病中孕妇接种疫苗的全面健康及社会价值的分类学研究 J. P. SevillaDaria BurnesDavid E. Bloom Pages: 651 - 682 Original Research（论著） 2 Characteristics of Haemophilus influenzae Isolates Responsible for Invasive Infections in Poland in 2018–2023 2018-2023年波兰引起侵袭性感染的流感嗜血杆菌分离株的特征 Marlena KiedrowskaKinga BłaszczykAnna Skoczyńska Pages: 683 - 700 3 Evaluating the Effectiveness of 2024–2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study 评估2024-2025年季节性mRNA-1273疫苗对美国≥18岁成年人预防与COVID-19相关住院和就医的效力：一项观察性匹配队列研究 Nevena VicicAlina BogdanovAmanda Wilson Pages: 701 - 714 4 Elevated Plasma GDF-15 Levels Are Associated with Aging, Multimorbidity, and Tobacco Exposure in People with HIV HIV感染者中血浆GDF-15水平升高与衰老、多种合并症及烟草暴露相关 Aida López LópezJacobo Alonso DomínguezCoRIS Cohort Pages: 715 - 731 5 High Burden of Febrile Sub-microscopic Plasmodium Mixed Infections in Central India: A Cross-Sectional Study 印度中部无症状疟原虫混合感染伴发热疾病负担高：一项横断面研究 Nimita DeoraVeena PandeAbhinav Sinha Pages: 733 - 747 6 How Status Quo Bias Shapes Willingness, Uptake, and Adherence to PrEP Among Chinese MSM: A Behavioral Economics Perspective 从行为经济学视角看现状偏见如何影响中国男男性行为者对暴露前预防的意愿、接受度和依从性 Min ZhaoXiang ZhaoLei Zhang Pages: 749 - 767 7 Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged≥56 Years: A Phase III, Open-Label Study 四价脑膜炎球菌结合疫苗（MenACYW-TT）在≥56岁潜在朝觐/副朝觐者中的免疫原性和安全性：一项III期、开放标签研究 Ghassan S. DbaiboIsmail BalikMehmet Ceyhan Pages: 769 - 785 Part of 1 collection: Digital Features - Infectious Diseases 所属合集：数字专题 -传染病 8 Clinical Impact of Droplet Digital PCR-Guided Antibiotic Stewardship on Prognosis in Patients with Suspected Bloodstream Infection: A Prospective Observational Study 液滴数字PCR指导的抗生素管理对患者疑似血流感染预后的临床影响：一项前瞻性观察研究 Ziqiang ShaoJingwen ZhuBangchuan Hu Pages: 787 - 807 9 Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017–2024 2017-2024年美国下呼吸道疾病成人患者门诊呼吸道合胞病毒检测率 Katherine K. PerezKashmira DateElizabeth Begier Pages: 809 - 834 10 Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement 头孢地尔在治疗碳青霉烯类耐药非发酵革兰氏阴性杆菌（鲍曼不动杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌）感染中的作用：专家声明 Alexandre BleibtreuYoussef BennisCoRIS Cohort Pages: 835 - 857 11 IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273 重复接种mRNA-1273疫苗后IgG4中和作用及总IgG Fc效应功能的持续存在 Paulina KaplonekHarry BerteraCarole Henry Pages: 859 - 874 12 Rising Burden of Herpes Zoster among General Adults and Increased-Risk Groups in Eastern China, 2015–2021: A Population-Based Cohort Study 2015-2021年中国东部普通成人及高风险人群带状疱疹负担上升：一项基于人群的队列研究 Zhenwei LiShenjia GuChuanxi Fu Pages: 875 - 888 13 Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS PUNCH CD3-OLS研究中住院患者使用活菌粪便微生物群（Live-jslm）预防复发性艰难梭菌感染的安全性和有效性 Andrew M. SkinnerThomas P. LodiseJordan E. Axelrad Pages: 889 - 901 Letter（读者来信） 14 Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States” 致编辑的信：关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件” Keiji Konishi Pages: 903 - 905 15 A Response to: Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States” 回复：致编辑的信——关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件” Ching-Yi ChuoWoodie ZachryLi Tao Pages: 907 - 909 16 A Response to: “Letter to the Editor regarding ‘Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study'” 回复：致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究” Romain ArrestierKeyvan Razazi Pages: 911 - 914 17 Letter to the Editor regarding 'Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study' 致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究” Julien MassolValentin MauletFrédéric J. Baud Pages: 915 - 919 Infectious Diseases and Therapy Volume 15, Issue 4 感染性疾病与治疗 15卷 4期 https://link.springer.com/journal/40121/volumes-and-issues/15-4 Review（综述） 1 Outpatient Parenteral Antimicrobial Therapy (OPAT) in Italy: A Scoping Review 意大利门诊静脉注射抗菌药物治疗（OPAT）：一项范围综述 Chiara MorealSimone GiulianoCarlo Tascini Pages: 921 - 939 2 Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration—A Review 重新构想噬菌体疗法治疗多重耐药病原体：从生物银行到卫生系统整合——综述 Abay A. AyeleWenfeng LiuAbel A. Negash Pages: 941 - 957 3 Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review 探索病毒性肝炎药物领域：新发现与持久挑战。一篇叙述性综述 He-ming SunXing-yu WangYan-hang Gao Pages: 959 - 985 Original Research（论著） 4 Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality 儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联 Muhterem DuyuAyşe Aşık Pages: 987 - 1001 Publisher Correction（出版商更正） 5 Publisher Correction: Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality 出版商更正：儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联 Muhterem DuyuAyşe Aşık Pages: 1003 - 1005 Original Research（论著） 6 A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19 用于从中和抗体滴度预测疗效以建立预防新冠肺炎单克隆抗体免疫桥接的统计免疫保护相关因素模型 Ilker YalcinLeijun HuMark A. Wingertzahn Pages: 1007 - 1017 7 Early Antibiotic Therapy in Sepsis Without Shock: A Multimethod Study of Heterogeneous Treatment Effects in ICU Patients 无休克性脓毒症的早期抗生素治疗：一项针对ICU患者异质性治疗效果的多方法研究 Peng ZhangTongkun ZuoYing Huang Pages: 1019 - 1033 8 Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2Years and Older in China 中国2岁及以上人群单独接种及与流感疫苗同时接种23价肺炎球菌多糖疫苗的上市后安全监测 Yun-feng ShiLin-hang JuHong-xing Pan Pages: 1035 - 1046 9 Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study 美国预防婴儿呼吸道合胞病毒下呼吸道感染：Nirsevimab和Clesrovimab的成本效益——一项建模研究 Benjamin YarnoffMatthieu BeuveletLeonard R. Krilov Pages: 1047 - 1073 10 Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study 西班牙和意大利奥利他万星治疗复杂血流感染和心内膜炎（ORIBAC研究）：一项回顾性多中心观察研究 Antonio VenaLaura MezzogoriORIBAC study group Pages: 1075 - 1092 11 Mitigating Vaccine Disparities Through Faith-Based Intervention: A Pre-Post Analysis of Recombinant Zoster Vaccine Knowledge and Acceptance in Socially Vulnerable Racial and Ethnic Minoritized Communities 通过基于信仰的干预措施减轻疫苗差异：对社会弱势的种族和少数民族群体重组带状疱疹疫苗认知和接受度的前后分析 Jacinda C. Abdul-MutakabbirRaheem Abdul-MutakabbirSamuel J. Casey Pages: 1093 - 1114 12 Epidemiological Burden and Hospitalization Trends of Human Metapneumovirus in Spain (2016–2023): A Retrospective Study 西班牙人类偏肺病毒的流行病学负担和住院趋势（2016 - 2023年）：一项回顾性研究 Oscar Brochado-KithRuth Gil-PrietoAngel Gil-de-Miguel Pages: 1115 - 1135 13 Using Real-World Data to Support Claim Expansion of the Cobas SARS-CoV-2 Test in Asymptomatic Testing: Data from the National Football League Occupational Surveillance Program 使用现实数据支持Cobas SARS-CoV-2检测在无症状检测中的适用范围扩大：来自美国国家橄榄球联盟职业监测计划的数据 Baiyu YangErin B. WassermanElodie Baumfeld Andre Pages: 1137 - 1148 Infectious Diseases and Therapy Volume 15, Issue 5 感染性疾病与治疗 15卷 5期 https://link.springer.com/journal/40121/volumes-and-issues/15-5 Review（综述） 1 Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review 四环素类药物治疗骨关节感染的有效性和安全性：文献综述 Paul Laffont-LozesRomaric LarcherAlbert Sotto Pages: 1149 - 1174 2 The Ongoing Challenge of Pertussis in Eastern and Northern Europe: Recommendations from the Global Pertussis Initiative 东欧和北欧百日咳持续存在的挑战：全球百日咳倡议的建议 Mine Durusu TanrioverUlrich HeiningerKevin Forsyth Pages: 1175 - 1201 3 Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review 细菌性前列腺炎的抗生素药代动力学及前列腺穿透性：系统综述 Rui GeXinwen NianZhuo Wang Pages: 1203 - 1248 4 Treatment for Dientamoeba fragilis: A Systematic Review and Meta-analysis 脆弱双核阿米巴病的治疗：系统综述和荟萃分析 Nadav BaharavMichael ItzkovichDafna Yahav Pages: 1249 - 1262 Original Research（论著） 5 Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors 结核病疫苗M72/AS01E实施准备工作：全球需求预测及关键影响因素 Judith KallenbergDominique MileaAgathe Philippot Pages: 1263 - 1279 Correction（更正） 6 Correction: Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors 更正：结核病疫苗M72/AS01E实施准备工作：全球需求预测及关键影响因素 Judith KallenbergDominique MileaAgathe Philippot Pages: 1281 - 1281 Original Research（论著） 7 Impact of Nirsevimab on Pediatric RSV-Related Lower Respiratory Tract Infections: A Retrospective Pre–Post Observational Study in Tuscany, Italy 尼塞韦单抗对意大利托斯卡纳地区儿童呼吸道合胞病毒相关下呼吸道感染的影响：一项回顾性前后对照观察研究 Francesco NiedduMarta VerzieriMaria Moriondo Pages: 1283 - 1295 8 Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study 尽管病毒学抑制，美国HIV感染者更换抗逆转录病毒疗法的情况并不少见：OPERA队列研究 Karam MounzerMichael D. OstermanGregory P. Fusco Pages: 1297 - 1314 9 Role of Community Associations in HIV, HBV and HCV Screening and Support for Migrant Populations in France: Results of the DéPAC Study 社区协会在法国移民人群HIV、HBV和HCV筛查及支持中的作用：DéPAC研究结果 Dulce AlfaiateJean-Claude TardyFrançois Durand Pages: 1315 - 1333 Part of 1 collection:Digital Features - Infectious Diseases 所属专题合集：数字专题-传染病 10 Impact of Risk Factor Combinations on Severe COVID-19 Outcomes Among Outpatients 风险因素联合作用对门诊患者严重新冠肺炎预后的影响 Haley J. AppanealVrishali V. LopesAisling R. Caffrey Pages: 1335 - 1351 11 Clinical Outcomes Among Older Adults Hospitalized with Respiratory Syncytial Virus and Influenza Infection: A Retrospective Analysis 老年住院患者呼吸道合胞病毒和流感病毒感染的临床预后：一项回顾性分析 Menucha JurkowiczIli MargalitMichal Mandelboim Pages: 1353 - 1367 12 The Impact and Effectiveness of a Two-Dose Varicella Immunization Program Among School Children: Evidence from Quasi-experimental Analyses 两剂水痘免疫接种计划对学龄儿童的影响和有效性：来自准实验分析的证据 Huiqiao GuXu XieYawen Jiang Pages: 1369 - 1384 13 Lessons Learned: Defining the Right Specifications for Diagnostics in Outbreak Situations 经验教训：疫情情况下确定诊断的正确规范 Markus BeutlerPablo BonvehíAndreas Wieser Pages: 1385 - 1399 14 Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022–2023 2022-2023年INFORM研究结果：英格兰地区普通人群和高危人群中新冠肺炎后严重流感的负担 Wilhelmine MeerausLucy CartyLance Turtle Pages: 1401 - 1424 15 Respiratory Syncytial Virus Immunization Strategies for Older Adults in Gulf Cooperation Council Countries: Expert Consensus and Recommendations 海湾合作委员会国家老年人呼吸道合胞病毒免疫接种策略：专家共识和建议 Nawal AlKaabiMohammed AbukhattabSalah Al Awaidy Pages: 1425 - 1449 16 Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD) 血液透析患者使用恩赛特韦治疗新冠肺炎的前瞻性研究（PROTECT-HD） Mineaki KitamuraTakahiro TakazonoHiroshi Mukae Pages: 1451 - 1466 17 Diagnostic Performance and Clinical Outcomes of Pertussis in Hospitalized Children in Relation to Available Vaccination Status: A Retrospective Cohort Study 在现有疫苗接种情况下，住院患儿百日咳的诊断性能和临床预后：一项回顾性队列研究 Dominika LachowiczBarbara JastrzębskaEdyta Podsiadły Pages: 1467 - 1477 18 Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA 使用现实数据证明Elecsys抗SARS-CoV-2抗核衣壳免疫检测的临床性能，以支持美国监管决策 Eldad A. HodBaiyu YangElodie Baumfeld Andre Pages: 1479 - 1491 19 Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis 格卡瑞韦/哌仑他韦治疗慢性丙型肝炎病毒感染且伴有合并症或多种合并用药受试者的有效性和安全性：一项综合分析 Curtis CooperShweta A. RainaStanislas Pol Pages: 1493 - 1508 20 Modeling the Public Health Impact of Introducing 4CMenB Vaccination for Infants in the Brazilian National Immunization Program 在巴西国家免疫计划中引入4CMenB疫苗对公共卫生的影响建模 Thatiana PintoZeki KocaataElise Kuylen Pages: 1509 - 1524 21 Multicenter Real-World Outpatient Use of Intravenous Omadacycline 门诊使用静脉注射奥马环素的多中心现实情况 Lucinda J. Van AnglenCathy L. KooKimberly A. Couch Pages: 1525 - 1538 22 Burden of Respiratory Syncytial Virus in Older ADults in Nagasaki, Japan (Nagasaki ROAD): Preliminary Results (April 2024–March 2025) of a Prospective, Multicenter, Epidemiological Study 日本长崎地区老年人呼吸道合胞病毒负担（长崎ROAD）：一项前瞻性、多中心、流行病学研究的初步结果（2024年4月-2025年3月） Takahiro TakazonoNorihito KakuHiroshi Mukae Pages: 1539 - 1564 Brief Report（简报） 23 Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study) 对于病毒学抑制的HIV感染者，从利匹韦林或其他非核苷类逆转录酶抑制剂（NNRTI）为基础的抗逆转录病毒疗法转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的有效性：一项回顾性分析（DRIVE-SWITCH研究） Roberta GagliardiniAlessandro CaioliAndrea Antinori Pages: 1565 - 1575 Infectious Diseases and Therapy Volume 15, Issue 6 感染性疾病与治疗 15卷 6期 https://link.springer.com/journal/40121/volumes-and-issues/15-6 Commentary（述评） 1 Adult RSV Vaccination: What Is the Role of RSV Subgroup in Disease Prevention? 成人RSV疫苗接种：RSV亚群在疾病预防中的作用是什么？ S. Elizabeth WilliamsGiovanni Checcucci LisiElizabeth Begier Pages: 1577 - 1587 Review（综述） 2 Epidemiology of Acute Cystitis or Afebrile Urinary Tract Infection in Adult Men: A Systematic Literature Review 成年男性急性膀胱炎或无热尿路感染的流行病学：一项系统文献综述 Mary E. GeorgiouPriscilla WittkopfFanny S. Mitrani-Gold Pages: 1589 - 1606 3 Non-intravenous Amphotericin B: A Review of Localized Administration Routes 非静脉注射两性霉素B：局部给药途径综述 Francelise Bridi CavassinLaura Fernanda RodriguesMarcello Mihailenko Chaves Magri Pages: 1607 - 1632 4 Infections Caused by Fusobacterium Species: Microbiology, Clinical Syndromes and Management: A Narrative Review Fusobacterium属引起的感染：微生物学、临床综合征及治疗：一篇叙述性综述 Michal ParetGuy KatzenellenbogenDafna Yahav Pages: 1633 - 1647 5 When Culture Results Don’t Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making 当培养结果不能说明全部问题：临床决策中抗生素陷阱的实用综述 Ahmed M. ShomanAyman A. Radwan Pages: 1649 - 1667 Original Research（论著） 6 Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study 德国保护婴儿免受呼吸道合胞病毒感染的替代免疫策略的成本效益：一项决策模型研究 Caroline LadeErin QuinnAhuva Averin Pages: 1669 - 1687 7 Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review 越南带状疱疹及其并发症治疗相关费用估算：一项病历回顾研究 Nurilign AhmedVan M. NguyenHuong T. T. Nguyen Pages: 1689 - 1704 8 Validation of the VIRSTA and VIRSTA+ Scores to Identify Patients with Staphylococcus aureus Bacteremia at Very Low Risk of Infective Endocarditis VIRSTA和VIRSTA+评分验证以识别感染性心内膜炎极低风险的金黄色葡萄球菌菌血症患者 Daniela Malano-BarlettaMiguel Ángel VerdejoAlex Soriano Pages: 1705 - 1718 9 The Shifting Landscape of HIV–Tuberculosis Co-Infection in the MENA Region with a Focus on Saudi Arabia: A Systematic Epidemiological Analysis over Three Decades MENA地区HIV–结核共感染的变化格局：以沙特阿拉伯为重点的三十年系统流行病学分析 Zikria SaleemMasaad Saeed AlmutairiFaris S. Alnezary Pages: 1719 - 1731 10 Comprehensive Analysis of Health Service Utilization for Febrile Illness and Malaria in Malaria-Endemic States in India: LLINs as a Pillar of Control Strategies 印度疟疾流行邦发热疾病和疟疾卫生服务利用的综合分析：长效杀虫蚊帐作为控制策略的支柱 Vani H. ChalageriShrinivasa B. MarinaikAnupkumar R. Anvikar Pages: 1733 - 1746 11 Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C 格卡瑞韦/匹布他韦在韩国慢性丙型肝炎患者中的观察性上市后安全性和有效性监测 Jin-Woo LeeSang Hoon AhnJeong Heo Pages: 1747 - 1761 12 Post-Marketing Active Surveillance of Adverse Events Following Quadrivalent Subunit Influenza Vaccine in Healthy Participants Aged≥3 Years in China 中国≥3岁健康人群接种四价亚单位流感疫苗后不良事件的上市后主动监测 Mingwei WeiYu PanHongxing Pan Pages: 1763 - 1778 Systematic Review（系统综述） 13 Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus Detection in Children and Adults: A Systematic Literature Review 用于儿童和成人呼吸道合胞病毒检测的即时核酸扩增检测：一项系统文献综述 Kashmira DateKyle FowlerElizabeth Begier Pages: 1779 - 1799 Correction（勘误） 14 Correction: The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies 勘误：头孢唑林接种效应：MSSA治疗策略中被低估的因素 Prakhar SrivastavaElizabeth SingletonRazieh Kebriaei Pages: 1801 – 1801

100 项与硫酸阿米卡星脂质体相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00865	-	S01AA21 D06AX12 J01GB06	DB00479

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
非结核分枝杆菌感染	美国	Insmed, Inc.	2018-09-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
细胞内鸟分枝杆菌感染	临床3期	-	Insmed, Inc.	2015-05-27
铜绿假单胞菌感染	临床3期	-	Insmed, Inc.	2011-03-15
脓肿分枝杆菌感染	临床2期	美国	Insmed, Inc.	2012-04-19
脓肿分枝杆菌感染	临床2期	加拿大	Insmed, Inc.	2012-04-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02344004 \| NCT02628600 (CONVERT, Pubmed \| Infect Dis Ther)	临床3期	细胞内鸟分枝杆菌感染	4	Amikacin liposome inhalation suspension (ALIS) plus guideline-based therapy (GBT)	鹹觸獵淵鑰製製顧齋繭(廠鹹鹹鏇願憲鏇蓋餘糧) = 遞願選獵觸膚襯襯壓齋鹹鑰糧觸糧醖艱蓋淵淵 (膚廠淵顧廠鹽廠遞壓糧 )	积极	2025-11-04
				GBT alone	鹹觸獵淵鑰製製顧齋繭(廠鹹鹹鏇願憲鏇蓋餘糧) = 積積廠積網齋糧廠鏇壓鹹鑰糧觸糧醖艱蓋淵淵 (膚廠淵顧廠鹽廠遞壓糧 )
ATS2025	N/A	非结核分枝杆菌感染追加	43	ALIS	衊鏇築醖製齋簾鬱鹽觸(繭鹹繭淵糧鹹膚艱顧獵) = non-serious and did not result in substantial treatment discontinuation 糧簾網壓觸築繭積鑰餘 (糧艱淵遞築憲餘餘蓋醖 ) 更多	积极	2025-05-16
NCT01316276 (CLEAR-110, Pubmed \| J Cyst Fibros)	临床3期	铜绿假单胞菌感染	206	Amikacin liposome inhalation suspension (ALIS)	範繭衊鑰壓鏇網淵築繭(獵網襯齋淵築製構構襯) = Twenty-one patients (10.2%) discontinued treatment due to a TEAE (mostly infective pulmonary exacerbation of CF) 鹹願衊遞鏇廠鹹襯鑰憲 (觸膚襯獵窪遞膚淵壓繭 ) 更多	积极	2021-06-15
				Tobramycin inhalation solution (TIS)
ATS2021	N/A	细胞内鸟分枝杆菌感染	-	Amikacin Liposome Inhalation Suspension (ALIS)	獵觸獵糧淵網繭鬱廠製(糧簾鏇蓋窪築膚鹽膚製) = The most common adverse events reported included bronchospasm, cough, dysphonia, and upper airway irritation, with each resulting in an average number of days to discontinuation below 90 days. 憲醖壓簾鑰衊艱淵選選 (製觸餘觸憲選醖築範淵 ) 更多	不佳	2021-05-03
NCT02344004 (CONVERT, Pubmed \| Chest)	临床3期	肺部疾病	336	Amikacin Liposome Inhalation Suspension + Guideline-based therapy	遞願艱製齋廠製構鬱窪(願餘製繭鏇襯膚淵鏇鏇) = Common adverse events among ALIS+GBT-treated patients (dysphonia, cough, dyspnea, hemoptysis) mainly occurred within the first 8 months of treatment 選積淵繭遞膚鏇鏇糧簾 (築範願顧艱範鏇遞醖艱 ) 更多	-	2021-04-19
				Guideline-based therapy alone
NCT02344004 \| NCT01315236 (Pubmed \| Eur J Drug Metab Pharmacokinet)	临床2/3期	肺部疾病	-	Amikacin Liposome Inhalation Suspension (ALIS) 590 mg	糧積糧窪觸糧壓願獵齋(餘襯餘鹽齋衊鏇簾糧繭) = 製積積遞糧願製築醖醖願壓鹹觸憲壓膚鹽鹹鑰 (衊願鏇窪憲廠衊築蓋餘 )	-	2021-03-01
NCT01315236 (CTgov)	临床2期	非结核分枝杆菌感染 \| 脓肿分枝杆菌感染 \| 细胞内鸟分枝杆菌感染	90	Liposomal amikacin for inhalation (LAI) (LAI 590 mg QD)	鹽艱鑰獵蓋壓壓淵繭齋 = 遞襯築齋網鹹觸願鑰選廠膚繭鹹顧觸製繭淵網 (鑰艱構鹽築齋廠築積襯, 壓艱築膚簾觸憲醖顧鏇 ~ 願選簾糧鹹築衊觸蓋繭) 更多	-	2019-08-21
				placebo (Placebo)	鹽艱鑰獵蓋壓壓淵繭齋 = 壓鏇獵膚壓衊鹹構淵窪廠膚繭鹹顧觸製繭淵網 (鑰艱構鹽築齋廠築積襯, 夢衊築鏇築鑰夢淵鏇艱 ~ 積鹹衊襯遞網醖壓顧構) 更多
NCT01316276 (CLEAR-110, CTgov)	临床3期	铜绿假单胞菌感染	206	liposomal amikacin	網鑰糧壓顧廠願願鑰衊 = 淵簾艱夢繭範積選觸衊齋衊衊鹹鏇獵膚範觸淵 (醖淵衊繭網遞簾艱網蓋, 繭遞簾繭製繭獵窪蓋網 ~ 築衊網蓋簾願艱糧鹹製) 更多	-	2019-07-26
NCT00775138 (CTgov)	临床2期	铜绿假单胞菌感染	64	Arikace (Arikace™ 280 mg)	簾鹹顧鏇鏇鹽憲鬱淵築 = 鬱齋鑰鹹餘艱憲衊蓋膚壓憲遞積繭範膚醖衊鹹 (選範膚鹽窪製簾網壓繭, 齋積艱築遞網鏇繭膚鑰 ~ 醖淵餘築顧繭餘醖繭夢) 更多	-	2019-07-10
				Placebo (Matching Placebo (280 mg))	簾鹹顧鏇鏇鹽憲鬱淵築 = 簾鹹鹽簾夢繭鹹壓積繭壓憲遞積繭範膚醖衊鹹 (選範膚鹽窪製簾網壓繭, 艱範構築繭構積鏇鹹願 ~ 遞鬱襯襯鹹淵衊鑰糧鑰) 更多
NCT01315678 (CTgov)	临床3期	铜绿假单胞菌感染	302	Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. (Arikayce™)	遞網繭膚積齋糧壓淵觸(壓鑰衊壓憲齋鬱積糧憲) = 願衊鑰淵餘鹽鹹糧遞鏇蓋觸膚範蓋選膚廠獵選 (築窪淵膚憲餘遞顧構鏇, 13.930) 更多	-	2019-06-24
				Tobramycin inhalation solution using a PARI LC® Plus nebulizer. (TOBI®)	遞網繭膚積齋糧壓淵觸(壓鑰衊壓憲齋鬱積糧憲) = 夢憲鬱構範獵淵顧鑰齋蓋觸膚範蓋選膚廠獵選 (築窪淵膚憲餘遞顧構鏇, 16.050) 更多